Market Research Report
Advanced Cancer Therapy with Next-Generation Immunotherapy Approach: Future Prospects (Opportunities and Challenges)
|Published by||DelveInsight Business Research LLP||Product code||924080|
Delivery time: 1-2 business days
|Advanced Cancer Therapy with Next-Generation Immunotherapy Approach: Future Prospects (Opportunities and Challenges)|
|Published: will be released March 4, 2020||Content info:||
The next generation immunotherapies pose a great potential to be a next in line chosen treatment for cancer after surgery, cytotoxic chemotherapy, radiation, and targeted therapy. The advancements in the Next generation immunotherapies generates interest in several targets such as ICOS, OX-40, LAG-3, TIM-3, B7-H3, VISTA and many more. Inhibitory and stimulatory pathways of different immune checkpoints assists the scientist and researchers to move a step forward.
However, the current scenario holds multi-level challenge for the further progress. One of the major challenge is scantiness in identification of the major biomarkers generating a need for distinct clinical study designs for the evaluation of efficacy. Additionally, other factors such as assessment of the efficacious immunotherapies required to develop successful strategies is another unmet need.
Worthwhile, the emerging trend in Next generation immunotherapies with continuous headway movement along with new emerging technologies for the development of targeted therapies lightens the hopes for better therapeutic alternatives. Concurrently, the increased funding for R&D by big players and organizations have enthused the scientists to put pedal on metal for further innovations.
The lucrative opportunities in the field of discovery is directly translated from the competitive intensity for different targets. Presently, OX-40 wins the innovation race with maximum number of products followed by LAG-3, TIM-3 and ICOS respectively. On the other hand, B7-H3 and VISTA, have lesser number of products in the clinical trials and holds a chance to catch up to the sprint.
With respect to the phase of development, more than twenty are being evaluated for early stage. Nevertheless, quite a lot products are also being developed for pre-clinical and discovery stage. The moral for potential therapies in the future is boosted to witness more than five products in mid-stage of development. The inference for novelty and newfangled research can be derived from the fewer number of products in late stage with one products in phase III and two in phase II/III. The front-runners for late-stage products belongs to ICOS, B7-H3 and LAG-3.
It is also noteworthy to evaluate the potential of different targets in different oncology indications such as non-small Cell Lung Carcinoma, head and neck cancer, multiple myeloma, gastric cancer, hepatocellular carcinoma, colorectal cancer, breast cancer, melanoma and many more. Bearing in mind the prospective of Next generation immunotherapies, several key players such as GlaxoSmithKline, Jounce Therapeutics, Pfizer, AstraZeneca, Bristol-Myers Squibb, Novartis, Merck are sinking their teeth into advance research and development. Furthermore, to strengthen the pipeline, many companies are entering into other indications such as osteosarcoma, renal cell carcinoma, wilms tumor, endometrial carcinoma, cervical cancer and others.
The market size for LAG-3 and ICOS targeted immunotherapies is anticipated to capture the major market share followed by TIM-3 and OX-40. The widespread scope and robust pipeline of Next generation immunotherapies has added enthusiasm and optimism for the impending therapies.
In this report we have captured the commercial potential of all potential next generation immunotherapies coming in oncology space targeting multiple indications in next 10-15 years.